Lilly Pleads Guilty To Off-Label Evista Promotion

The company will pay a $36 mil. fine for promoting the osteoporosis drug for reduction in breast cancer risk.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet